Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Odyssey Research
mi
from
Fargo, ND
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Odyssey Research
mi
from
Fargo, ND
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Dr. Senders and Associates
mi
from
Cleveland, OH
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Dr. Senders and Associates
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Calcagno Research & Development
mi
from
Gresham, OR
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Calcagno Research & Development
mi
from
Gresham, OR
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Children's Health Care - West
mi
from
Erie, PA
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Children's Health Care - West
mi
from
Erie, PA
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
University Of Pittsburgh Medical Center
mi
from
Greenville, PA
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
University Of Pittsburgh Medical Center
mi
from
Greenville, PA
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Family Healthcare Partners
mi
from
Grove City, PA
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Family Healthcare Partners
mi
from
Grove City, PA
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Pediatric Associates of Latrobe
mi
from
Latrobe, PA
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Pediatric Associates of Latrobe
mi
from
Latrobe, PA
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Pediatric Alliance, PC
mi
from
Pittsburgh, PA
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Pediatric Alliance, PC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
South Hills Pediatrics
mi
from
Pittsburgh, PA
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
South Hills Pediatrics
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Primary Physicians Research, Inc.
mi
from
Pittsburgh, PA
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Primary Physicians Research, Inc.
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Primary Physicians Research
mi
from
Pittsburg, PA
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Primary Physicians Research
mi
from
Pittsburg, PA
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Laurel Pediatrics
mi
from
Uniontown, PA
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Laurel Pediatrics
mi
from
Uniontown, PA
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Family Practice Medical Associates South
mi
from
Upper St. Clair, PA
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Family Practice Medical Associates South
mi
from
Upper St. Clair, PA
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Children's Community Pediatrics
mi
from
Wexford, PA
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Children's Community Pediatrics
mi
from
Wexford, PA
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Jackson Clinic Professional Association
mi
from
Jackson, TN
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Jackson Clinic Professional Association
mi
from
Jackson, TN
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Benchmark Research Ft. Worth
mi
from
Fort Worth, TX
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Benchmark Research Ft. Worth
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Benchmark Research, San Angelo
mi
from
San Angelo, TX
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Benchmark Research, San Angelo
mi
from
San Angelo, TX
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Jean Brown Research
mi
from
Clinton, UT
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Jean Brown Research
mi
from
Clinton, UT
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Wee Care Pediatrics
mi
from
Layton, UT
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Wee Care Pediatrics
mi
from
Layton, UT
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Cottonwood Pediatrics
mi
from
Murray, UT
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Cottonwood Pediatrics
mi
from
Murray, UT
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
J. Lewis Research, Inc.
mi
from
Salt Lake City, UT
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
J. Lewis Research, Inc.
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Jean Brown Research
mi
from
Salt Lake City, UT
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Jean Brown Research
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Copperview Medical Center
mi
from
South Jordan, UT
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Copperview Medical Center
mi
from
South Jordan, UT
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Rockwood Clinic
mi
from
Spokane, WA
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Rockwood Clinic
mi
from
Spokane, WA
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
Rockwood Clinic North
mi
from
Spokane, WA
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
Rockwood Clinic North
mi
from
Spokane, WA
Click here to add this to my saved trials
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated:  1/19/2016
TASC Research Services Inc.
mi
from
Surrey,
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
Status: Enrolling
Updated: 1/19/2016
TASC Research Services Inc.
mi
from
Surrey,
Click here to add this to my saved trials
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Status: Enrolling
Updated:  1/19/2016
University of Colorado
mi
from
Aurora, CO
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Status: Enrolling
Updated: 1/19/2016
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Status: Enrolling
Updated:  1/19/2016
Emory University
mi
from
Atlanta, GA
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Status: Enrolling
Updated: 1/19/2016
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
Status: Enrolling
Updated:  1/20/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
Status: Enrolling
Updated: 1/20/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Status: Enrolling
Updated:  1/20/2016
Houston Medical Center Building
mi
from
Houston, TX
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Status: Enrolling
Updated: 1/20/2016
Houston Medical Center Building
mi
from
Houston, TX
Click here to add this to my saved trials
Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia
Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia: The FFAME Study
Status: Enrolling
Updated:  1/21/2016
Clinical and Translational Research Center (CTRC); Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia
Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia: The FFAME Study
Status: Enrolling
Updated: 1/21/2016
Clinical and Translational Research Center (CTRC); Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
OTO-201 for the Treatment of Otitis Externa
A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Administration for Treatment of Otitis Externa
Status: Enrolling
Updated:  1/21/2016
Email Otonomy Central Contact for Trial Locations
mi
from
San Diego, CA
OTO-201 for the Treatment of Otitis Externa
A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Administration for Treatment of Otitis Externa
Status: Enrolling
Updated: 1/21/2016
Email Otonomy Central Contact for Trial Locations
mi
from
San Diego, CA
Click here to add this to my saved trials
Universal Screening for Tuberculosis and Anemia With the CHICA System
Universal Screening for Tuberculosis and Anemia With the CHICA System
Status: Enrolling
Updated:  1/22/2016
Children's Health Services Research
mi
from
Indianapolis, IN
Universal Screening for Tuberculosis and Anemia With the CHICA System
Universal Screening for Tuberculosis and Anemia With the CHICA System
Status: Enrolling
Updated: 1/22/2016
Children's Health Services Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Behavioral Therapy Development for Methamphetamine Abuse
Behavioral Therapy Development for Methamphetamine Abuse
Status: Enrolling
Updated:  1/26/2016
UCLA Center for Clinical AIDS Research and Education (CARE) Clinic
mi
from
Los Angeles, CA
Behavioral Therapy Development for Methamphetamine Abuse
Behavioral Therapy Development for Methamphetamine Abuse
Status: Enrolling
Updated: 1/26/2016
UCLA Center for Clinical AIDS Research and Education (CARE) Clinic
mi
from
Los Angeles, CA
Click here to add this to my saved trials
OTIS Autoimmune Diseases in Pregnancy Project
Humira (Adalimumab) Pregnancy Exposure Registry: OTIS Rheumatoid Arthritis in Pregnancy Project
Status: Enrolling
Updated:  1/26/2016
The University of California, San Diego
mi
from
La Jolla, CA
OTIS Autoimmune Diseases in Pregnancy Project
Humira (Adalimumab) Pregnancy Exposure Registry: OTIS Rheumatoid Arthritis in Pregnancy Project
Status: Enrolling
Updated: 1/26/2016
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis
Comparing NAAT Testing to Standard Methods in Diagnosis of Vaginal Infections in the General Gynecology and Vulvovaginal Referral Offices.
Status: Enrolling
Updated:  1/26/2016
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis
Comparing NAAT Testing to Standard Methods in Diagnosis of Vaginal Infections in the General Gynecology and Vulvovaginal Referral Offices.
Status: Enrolling
Updated: 1/26/2016
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Molecular Epidemiology of Clostridium Difficile Infections in Children
Molecular Epidemiologic Survey and Risk Factor Assessment of Clostridium Difficile Infections in Children: A Focus on Recurrent and Community-associated Infections
Status: Enrolling
Updated:  1/26/2016
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Molecular Epidemiology of Clostridium Difficile Infections in Children
Molecular Epidemiologic Survey and Risk Factor Assessment of Clostridium Difficile Infections in Children: A Focus on Recurrent and Community-associated Infections
Status: Enrolling
Updated: 1/26/2016
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Randomized Controlled Trial of Antibiotics in the Management of Children With Community-Acquired Abscess
Randomized Controlled Trial of Antibiotics in the Management of Children With Community-Acquired Skin and Soft Tissue Abscess Undergoing Incision and Drainage
Status: Enrolling
Updated:  1/27/2016
Ann and Robert H. Lurie Children's Hospital
mi
from
Chicago, IL
Randomized Controlled Trial of Antibiotics in the Management of Children With Community-Acquired Abscess
Randomized Controlled Trial of Antibiotics in the Management of Children With Community-Acquired Skin and Soft Tissue Abscess Undergoing Incision and Drainage
Status: Enrolling
Updated: 1/27/2016
Ann and Robert H. Lurie Children's Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid
Phase 2b, Two-part, Open-label, Uncontrolled Study to Evaluate Safety, Tolerability, and Immunogenicity of a Single 40-µg Dose of Recombinant Botulinum Vaccine A/B (rBV A/B) for the Production of BabyBIG® in Volunteers Previously Immunized With Pentavalent Botulinum Toxoid for Occupational Protection
Status: Enrolling
Updated:  1/27/2016
California Department of Public Health
mi
from
Richmond, CA
Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid
Phase 2b, Two-part, Open-label, Uncontrolled Study to Evaluate Safety, Tolerability, and Immunogenicity of a Single 40-µg Dose of Recombinant Botulinum Vaccine A/B (rBV A/B) for the Production of BabyBIG® in Volunteers Previously Immunized With Pentavalent Botulinum Toxoid for Occupational Protection
Status: Enrolling
Updated: 1/27/2016
California Department of Public Health
mi
from
Richmond, CA
Click here to add this to my saved trials
Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid
Phase 2b, Two-part, Open-label, Uncontrolled Study to Evaluate Safety, Tolerability, and Immunogenicity of a Single 40-µg Dose of Recombinant Botulinum Vaccine A/B (rBV A/B) for the Production of BabyBIG® in Volunteers Previously Immunized With Pentavalent Botulinum Toxoid for Occupational Protection
Status: Enrolling
Updated:  1/27/2016
Batelle Biomedical Research Center
mi
from
West Jefferson, OH
Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid
Phase 2b, Two-part, Open-label, Uncontrolled Study to Evaluate Safety, Tolerability, and Immunogenicity of a Single 40-µg Dose of Recombinant Botulinum Vaccine A/B (rBV A/B) for the Production of BabyBIG® in Volunteers Previously Immunized With Pentavalent Botulinum Toxoid for Occupational Protection
Status: Enrolling
Updated: 1/27/2016
Batelle Biomedical Research Center
mi
from
West Jefferson, OH
Click here to add this to my saved trials
Empyema Treated With tPA & DNAse
Prospective Randomized Trial: Fibrinolysis With tPA (Tissue Plasminogen Activator) Versus tPA and DNAse in Children With Empyema
Status: Enrolling
Updated:  1/27/2016
Children's Mercy Hospital
mi
from
Kansas City, MO
Empyema Treated With tPA & DNAse
Prospective Randomized Trial: Fibrinolysis With tPA (Tissue Plasminogen Activator) Versus tPA and DNAse in Children With Empyema
Status: Enrolling
Updated: 1/27/2016
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Cranberry Proanthocyanidins for Modification of Intestinal E. Coli Flora and Prevention of Urinary Tract Infections in UTI-Susceptible Women
Cranberry Proanthocyanidins for Modification of Intestinal E. Coli Flora and Prevention of Urinary Tract Infections in UTI-Susceptible Women
Status: Enrolling
Updated:  1/28/2016
University of Wisconsin-Madison
mi
from
Madison, WI
Cranberry Proanthocyanidins for Modification of Intestinal E. Coli Flora and Prevention of Urinary Tract Infections in UTI-Susceptible Women
Cranberry Proanthocyanidins for Modification of Intestinal E. Coli Flora and Prevention of Urinary Tract Infections in UTI-Susceptible Women
Status: Enrolling
Updated: 1/28/2016
University of Wisconsin-Madison
mi
from
Madison, WI
Click here to add this to my saved trials
Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single-Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
Status: Enrolling
Updated:  1/28/2016
Quintiles, Inc.
mi
from
Overland Park, KA
Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single-Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
Status: Enrolling
Updated: 1/28/2016
Quintiles, Inc.
mi
from
Overland Park, KA
Click here to add this to my saved trials
Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Chula Vista, CA
Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
San Diego, CA
Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
St. Louis, MO
Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Somers Point, NJ
Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Somers Point, NJ
Click here to add this to my saved trials
Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Status: Enrolling
Updated:  1/29/2016
Research Site
mi
from
Cordoba,
Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Status: Enrolling
Updated: 1/29/2016
Research Site
mi
from
Cordoba,
Click here to add this to my saved trials
A Study Comparing Ceftazidime-Avibactam+Metronidazole Versus Meropenem in Adults With Complicated Intra-abdominal Infections
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Stanford, CA
A Study Comparing Ceftazidime-Avibactam+Metronidazole Versus Meropenem in Adults With Complicated Intra-abdominal Infections
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study Comparing Ceftazidime-Avibactam+Metronidazole Versus Meropenem in Adults With Complicated Intra-abdominal Infections
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Torrance, CA
A Study Comparing Ceftazidime-Avibactam+Metronidazole Versus Meropenem in Adults With Complicated Intra-abdominal Infections
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials